VIVUS, Inc. (NASDAQ:VVUS) Goes Alone With Qsymia


Dallas, Texas 03/19/2014 (FINANCIALSTRENDS) –  VIVUS, Inc. (NASDAQ:VVUS) is the Mountain View, California-based biopharma company, which has a line of drugs fighting sleep apnea to overweight or diabetes. One of its currently popular drugs, used for weight-management and fighting obesity is Qsymia. However, this is a drug recommended with a diet which is calorie-deficient. The efficacy of the drug is optimized when physical activity too is increased or a strict exercise regime is followed. The initial body mass index in adults at 30 or higher are also indicative of two conditions – hypertension or type 2 diabetes mellitus and higher cholesterol.

VIVUS, Inc.(NASDAQ:VVUS) in its Qsymia drug, has in fact combined two active ingredients from its previously approved drugs. These ingredients are Phentermine as well as topiramate.

Interestingly, VIVUS, Inc.(NASDAQ:VVUS)’s Qsymia has also finished with the second phase of clinical studies for treating two diverse health conditions. The first is sleep apnea and the second type 2 diabetes. Other ingredients known to be included are avanafil or Stendra.

VIVUS, Inc.(NASDAQ:VVUS) has actually had a tough approval-phase for Qsymia, receiving approval as late as 2012. The reasons for the rigorous approval process for weight-loss drugs by FDA was the fen-phen weight loss drug, which though approved by FDA, resulted in major issues.

The current competitors for VIVUS’s Qsymia in the weight-loss drug category are Arena and Orexigne. But VIVUS woes are now overflowing post the activist-led ousting of the management for lack of foresight in introducing Qsymia. The management has rather bullheadly chosen to introduce the drug into the market, without back-up from any other channels, doctors, education or insurance-claims. This had led to zero-growth in the sale of the drug.

VIVUS holds a market capital of $616.60 million and trades on the stock market at infra-day prices of $6.00 to $6.11.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.